Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) released its earnings results on Monday. The company reported ($0.16) EPS for the quarter, FiscalAI reports. The firm had revenue of $3.05 million during the quarter.
Hillstream Biopharma Price Performance
Shares of NASDAQ CNTN opened at $1.71 on Monday. The stock has a market capitalization of $136.25 million, a PE ratio of -3.42 and a beta of 1.49. Hillstream Biopharma has a one year low of $1.66 and a one year high of $5.83. The business’s fifty day moving average price is $2.09 and its 200-day moving average price is $2.63.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on CNTN. Weiss Ratings downgraded shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Wall Street Zen cut shares of Hillstream Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.
Read Our Latest Stock Analysis on CNTN
About Hillstream Biopharma
Hillstream BioPharma is a biotechnology company focused on developing experimental treatments for cancer, particularly drug-resistant tumors and cancer stem cells. Its research centers on ferroptosis, a form of cell death that may offer a way to attack cancer cells that are difficult to treat with existing therapies. The company’s development work includes its LION platform, which uses liposomal iron oxide nanoparticles to deliver iron to cancer cells and promote ferroptosis. Hillstream has described HSB-1216 as a potential cancer treatment based on this approach.
Featured Stories
- Five stocks we like better than Hillstream Biopharma
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Hillstream Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
